• Recurrent digestive symptoms: bloating, abdominal discomfort or altered bowel habits.
• Fatigue: persistent tiredness or reduced energy levels.
• Skin symptoms: rashes, itching or recurrent skin irritation.
• Recurrent infections: frequent illness or slow recovery.
• Oral or genital symptoms: recurring discomfort or irritation.
• Dietary patterns: high intake of sugars, refined carbohydrates or yeast-containing foods.
• Medication history: repeated or prolonged use of antibiotics or steroid medications.
• Immune evaluation: investigation of immune responses linked to fungal exposure.

Immuno Candida (Immunodiffusion & IgG) assesses antibodies associated with Candida exposure using a venous blood sample. The panel includes IgG antibody measurement and immunodiffusion methods, which together provide information on immune recognition of Candida antigens.

Clinically, this test may be useful when individuals present with symptoms that raise consideration of fungal exposure or immune response to Candida. Antibody testing can offer insight into how the immune system has interacted with Candida over time, particularly in individuals with relevant symptom patterns or exposure history.

Practitioners typically interpret results alongside clinical history, dietary habits, medication use and other laboratory findings. When reviewed in context, the test can support informed discussions with clients about immune responses related to Candida and symptom patterns that may warrant further exploration.

Practical

Specimen requirements:

Serum. Blood drawn.

This test requires a blood draw, so please ensure you can refer to a phlebotomist in the clients area before you order this test.

(Nordic Laboratories accepts no cost or claims related to any phlebotomy services in the event of sample rejection or failure for any reason. By ordering this, or any test requiring phlebotomy services, you accept any inherent risk and any associated costs.)

Average processing time:

14 ±8 days

Research

• Abu-Elteen KH. The influence of dietary carbohydrates on in vitro adherence of four Candida species to human buccal epithelial cells. Microb Ecol Health Dis 2005; 17: 156-62.

• Jarvis WR. Epidemiology of Nosocomial Fungal Infections, with Emphasis on Candida Species. Clinical Infectious Diseases. 1995;20(6):1526-1530.

• Kennedy, M. J. and Volz, P.A., Effect of various antibiotics on gastrointestinal colonization and dissemination by Candida albicans, Sabouraudia, 23, 265–274, 1985.

• Lehmann PF, Reiss E. Comparison by Elisa of serum anti-Candida albicans mannan IgG levels of a normal population and in diseased patients. Mycopathologia. 1980;70(2):89-93.

• Montagna MT, Caggiano G, Borghi E, Morace G. The Role of the Laboratory in the Diagnosis of Invasive Candidiasis. Drugs. 2009;69(Supplement 1):59-63.

• Pires MFC, Corra B, Gambale W, Paula CR. Experimental model of Candida albicans (serotypes A and B) adherence in vitro. Braz J Microbiol 2001; 32: 163-9.

• Pizzo G, Giuliana G, Milici ME, Giangreco R. Effect of dietary carbohydrates on the epithelial adhesion of Candida albicans, Candida tropicalis, and Candida krusei. New Microbiol 2000; 23: 63-71.

• Seelig MS. The role of antibiotics in the pathogenesis of Candida infections. The American Journal of Medicine. 1966;40(6):887-917.

• Seligmann, E., Virulence enhancement of Candida albicans by antibiotics and cortisone. Proc. Soc. Exp. Biol. Med., 1953. 83: p. 778–781. 68.

• Vojdani A, Rahimian P, Kalhor H, Mordechai E. Immunological cross reactivity between Candida albicans and human tissue. J Clin Lab Immunol. 1996;48(1):1-15.